Recorded fact · drug.trial_access

drug.trial_access for enzalutamide

One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 0f0e6ec0 resolves to.

The record

Fact id	`0f0e6ec03802f1ae53dd569a`
Entity	drug: enzalutamide
Field	drug.trial_access
Source	clinicaltrials.gov
Read on	2026-11-07T06:34:32.466Z
Source version	clinicaltrials-api-2.0.5-data-2026-11-06T10:00:05
Method	api
Verification	machine_read
Licence	Terms and Conditions (last updated 2023-01-31) READ in full 2026-11-07: data free to all requesters; reuse allowed on conditions: attribute ClinicalTrials.gov, keep data current, display the date the registry processed the data, state any modifications; do not represent the data as other than a US Government database; no use of extracted email addresses for marketing; some records may carry third-party copyright (consult the submitter) and the data carry an international copyright outside the US. API rate guidance page UNREAD (JS page rendered no text 2026-11-07). AMBER because of the third-party copyright caveat on submitter text; counts and ids are safe, long free text is not reproduced. \| DISPLAY CONDITIONS (any page or delivery using this source): attribute ClinicalTrials.gov, show the registry processing date, state our modifications, never present as other than a US Government database, never use extracted emails for marketing.
Edition	2026-11, Merkle root `006ab9a329709cbe...`

This fact carries no verifying quote; its source is the dataset named above.

The value

{
 "ingredient": "ENZALUTAMIDE",
 "recruitingInterventionalCount": 81,
 "notYetRecruitingCount": 16,
 "byPhase": {
  "PHASE2": 28,
  "PHASE3": 23,
  "PHASE1": 15,
  "PHASE1/PHASE2": 13,
  "NA": 2
 },
 "trials": [
  {
   "nctId": "NCT07287150",
   "briefTitle": "A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "Hoffmann-La Roche",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-06",
   "startDate": "2026-03-11",
   "conditions": [
    "Metastatic Castration-Resistant Prostate Cancer"
   ],
   "countries": [
    "United States",
    "Australia",
    "Brazil",
    "Canada",
    "France",
    "Germany",
    "Italy",
    "Mexico",
    "South Korea",
    "Spain"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07287150"
  },
  {
   "nctId": "NCT03899155",
   "briefTitle": "Pan Tumor Rollover Study",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "Bristol-Myers Squibb",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-06",
   "startDate": "2019-08-09",
   "conditions": [
    "Cancer"
   ],
   "countries": [
    "United States",
    "Argentina",
    "Australia",
    "Austria",
    "Belgium",
    "Brazil",
    "Canada",
    "Chile",
    "China",
    "Czechia"
   ],
   "url": "https://clinicaltrials.gov/study/NCT03899155"
  },
  {
   "nctId": "NCT06136624",
   "briefTitle": "Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Merck Sharp & Dohme LLC",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-05",
   "startDate": "2023-12-31",
   "conditions": [
    "Prostate Cancer Metastatic"
   ],
   "countries": [
    "United States",
    "Argentina",
    "Australia",
    "Austria",
    "Brazil",
    "Canada",
    "Chile",
    "China",
    "Colombia",
    "Czechia"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06136624"
  },
  {
   "nctId": "NCT07751133",
   "briefTitle": "Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "University College, London",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-04",
   "startDate": "2026-08-28",
   "conditions": [
    "Prostate Cancer",
    "mHSPC",
    "mCRPC"
   ],
   "countries": [
    "United Kingdom"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07751133"
  },
  {
   "nctId": "NCT07723248",
   "briefTitle": "A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "ORIC Pharmaceuticals",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-03",
   "startDate": "2026-08-03",
   "conditions": [
    "Metastatic Castration Resistant Prostate Cancer"
   ],
   "countries": [
    "United States",
    "Puerto Rico"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07723248"
  },
  {
   "nctId": "NCT05818683",
   "briefTitle": "A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer",
   "phase": [
    "PHASE1"
   ],
   "leadSponsor": "Janssen Research & Development, LLC",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-03",
   "startDate": "2023-04-26",
   "conditions": [
    "Metastatic Castration-resistant Prostate Neoplasms",
    "Metastatic Hormone-sensitive Prostate Cancer"
   ],
   "countries": [
    "United States",
    "Australia",
    "Spain"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05818683"
  },
  {
   "nctId": "NCT06632977",
   "briefTitle": "Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "Alliance for Clinical Trials in Oncology",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-03",
   "startDate": "2025-02-06",
   "conditions": [
    "Castration-Resistant Prostate Carcinoma",
    "Stage IVB Prostate Cancer AJCC v8"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06632977"
  },
  {
   "nctId": "NCT05873192",
   "briefTitle": "Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "M.D. Anderson Cancer Center",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-02",
   "startDate": "2025-06-03",
   "conditions": [
    "Prostate Cancer"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05873192"
  },
  {
   "nctId": "NCT06499870",
   "briefTitle": "Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "Sean Sachdev",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-30",
   "startDate": "2024-09-06",
   "conditions": [
    "Prostate Adenocarcinoma"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06499870"
  },
  {
   "nctId": "NCT06629779",
   "briefTitle": "A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Pfizer",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-30",
   "startDate": "2024-10-22",
   "conditions": [
    "Metastatic Castration-Resistant Prostate Cancer"
   ],
   "countries": [
    "United States",
    "Argentina",
    "Brazil",
    "Bulgaria",
    "Canada",
    "Chile",
    "China",
    "Czechia",
    "Denmark",
    "Finland"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06629779"
  },
  {
   "nctId": "NCT06922318",
   "briefTitle": "The COSMYC Trial (COmbined Suppression of MYC)",
   "phase": 
... (shortened here; the full value is in the JSON twin)

SHA-256 of the exact stored value: af1f370090656eb6b94de85c11bb8aaa9f5cb7aec552f3aa58ca554dd68878ac.

This fact as data (JSON) · Check an answer against its receipt · Licence

Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.